The present disclosure provides methods of evaluating a therapeutic agent for cancer, and methods of cancer treatment.

Provided herein are carrier cells and virus combinations and methods for treatment of cancers. Also provided are modified carrier cells for such treatment, and methods of selecting carrier cells that are matched to subjects for such treatment.

A method to recover an extracellular vesicle at a high efficiency, including (a) and (b): wherein (a) is mixing (i) an extracellular vesicle-containing sample, (ii) particles on which a substance having an affinity to extracellular vesicle membrane is immobilized, and (iii) a polymer to give a mixture solution containing (i′) target particles bound to the extracellular vesicle via the substance and (ii′) the polymer; and (b) separating the target particles from the mixture solution. The method further includes reducing a viscosity of the mixture solution between (a) and (b). A method for analyzing an extracellular vesicle. A kit having (a) a polymer, (b) a substance having an affinity to the extracellular vesicle membrane, and (c) an enzyme capable of degrading a polymer.

The present describes monoclonal antibody to MUC1*.

The present application relates to a plasma polymer thin film and a method for preparing the same, the plasma polymer thin film prepared using a first precursor material represented by the following Chemical Formula 1:

##STR00001##

(In Chemical Formula 1,

R.sub.1 to R.sub.9 are each independently H or a C.sub.1-C.sub.5 substituted or unsubstituted alkyl group, and when R.sub.1 to R.sub.9 are substituted, the substituent is an amino group, a hydroxyl group, a cyano group, a halogen group, a nitro group, or a methoxy group).

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

The invention relates to a method of isolating a T cell that expresses a T cell receptor capable of binding specifically to an antigen presented by a cancer cell in association with an MR1 molecule. The method comprises the steps of (a) providing a preparation of T cells, (b) contacting the preparation with cancer cells expressing MR1 protein; (c) isolating a T cell that is specifically reactive to said cancer cells. The invention further relates to a method of preparing a T cell preparation expressing select MR1 recognizing T cell receptors from transgene expression vectors, the use of such T cell preparations in treatment of cancer, and to collections of MR1 reactive T cell receptor encoding nucleic acids and cells.

The invention provides a method for preparing an ordered cell-containing microarray, and a system for preparing an ordered cell-containing microarray.

The present invention is related to a biochip and production method thereof. The biochip comprises a carrier, a cell or tissue culture area deposited on the carrier, and a sensor area deposited on the carrier adjacent and fluidly communicating with the cell or tissue culture area. A containing space is contained in the cell or tissue culture area comprising a simulated vascular channel, a cell or a tissue and a culture medium. At least one sensor fixation area is contained at the sensor area for placing a sensor element. The present invention can be a model for stimulating cancer of specific patient to realtimely reflecting the cancer formation, transferring status and treatment strategies. The biochip could also carry testing drugs to observe how the drugs functioning to the cells/tissue as to provide a more accurate instruction of the drugs. The present invention can perform multiple test just within on chip which can save cost and also provide a more accurate test model for the patient.

Present invention is related to a tumor microenvironment on chip or a biochip for cell therapy having a carrier, a first cell or tissue culture area and a second cell or tissue area imbedded within the carrier. The present invention provides a biochip successfully cooperating micro fluidic technology and cell culture achieving the goal for detecting or testing the function of cell therapy for cancer or tumor.